



February 28, 2019
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

Completion of the enrollment of the final patient in the Phase III study for ophthalmologic biosimilar

Senju Pharmaceutical Co., Ltd. (hereinafter “Senju”) and Gene Techno Science Co., Ltd. (hereinafter “GTS”) announced the enrollment of the final patient in the Phase III study for biosimilar in ophthalmologic field was completed.

This product will improve the symptoms of patients with ophthalmic disorder such as age-related macular degeneration. The market size of biologics in this field in 2017 is estimated as 833 oku-yen in Japan and 10,500 oku-yen in the overseas market *1. Since we have faced with aging society in Japan, the number of patients is increasing, and indeed, as far as age-related macular degeneration is only concerned t was said to already reach 69 million patients in 2007 *2.

Senju initiated the Phase III study in November, 2017 and has just completed the enrollment of the final patients this month. GTS and Senju will continue to drive business collaboration in order to obtain marketing authorization in Japan. Furthermore, GTS pursues the opportunities to license out this product to overseas partners in collaboration with Senju

The impact by this progress on the financial performance of GTS for the fiscal year ending March 2019 will be minimal.

*1 calculated based on financial information of each company which markets the relevant drugs

*2 quoted from the website of Japanese Intractable Disease Information Center (as of November, 2017)